Erica Fischer-Cartlidge Discusses Oral Mucositis Treatment for Patients Taking an mTOR Inhibitor
Erica Fischer-Cartlidge MSN, CNS, CBCN, AOCNS, Clinical Nurse Specialist, Outpatient Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the difference between oral mucositis in patients receiving chemotherapy and patients taking an mTOR inhibitor.
Erica Fischer-Cartlidge MSN, CNS, CBCN, AOCNS, Clinical Nurse Specialist, Outpatient Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the difference between oral mucositis in patients receiving chemotherapy and patients taking an mTOR inhibitor.
Fischer-Cartlidge says when oral mucositis presents in a patient taking an mTOR inhibitor, it looks and acts differently than oral mucositis in patients receiving chemotherapy.
Fortunately, the oral mucositis in patients taking an mTOR inhibitor responds to steroids better than oral mucositis that presents in patients receiving chemotherapy. The steroid actually healed the oral mucositis instead of just controlling it, Fishcer-Cartlidge says, reducing the need for dose reduction.
<<<
UGN-102 Produces Comparable Responses Regardless of Surgery in NMIBC Subset
May 8th 2024Patients with newly diagnosed and recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer treated with UGN-102 displayed meaningful and similar responses and disease-free survival regardless of whether they underwent surgery.
Verification Nurse Provides ‘Significant Contribution to Patient Safety’ During Chemo Administration
May 1st 2024The role of a verification nurse can lead to several benefits, including the prevention of errors from reaching the patient, decreased workload, and potential cost savings from less drug waste.
